The development 5-lipoxygenase activating protein (FLAP) inhibitors has been an area of great interest to the pharmaceutical community due to their ability to interrupt the formation of a variety of pro-inflammitory leukotrienes (LTA4 - LTE4) that contribute to the pathophysiology of asthma and other inflammatory diseases. In our own effort to develop FLAP inhibitors, we have discovered a promising series of biaryl amino-heteroarenes. Structure activity relationships (SAR), cellular activity and species differences in potency will be presented.

Biaryl amino-heteroarenes as potent 5-lipoxygenase-activating protein inhibitors

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.